Interview with Viktor Shafranskyi, General Manager, IPSEN Ukraine
Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian…
Address: 36 Pushkinskaya street, O1004, Kiev,Ukraine
Tel: 380445026529
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.1 billion in 2010. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. In 2010, R&D expenditure totaled more than €220 million, above 20% of Group sales. The Group has total worldwide staff of close to 4,500 employees.
Ipsen started its activities in Ukraine 20 years ago, with the promotion of a group of legacy products, the majority of which were dedicated to the treatment of gastrointestinal diseases. A couple of years later, Ipsen introduced its innovative franchise, whose three main therapeutic areas are in oncology, endocrinology, and for the treatment of neuro-muscular disorders. For the moment, the company’s strategic focus is to expand its innovative franchise and to push these medicines forward into the market.
Over the past seven years, the range of strategic products in Ipsen’s Ukraine portfolio has more than doubled. At the beginning of 2004, about 30% of sales came from the innovative franchise, whereas by the end of this year, around 60% of sales is expected to be generated by innovative medicines.
In both its targeted therapeutic areas and primary care, Ipsen has a diversified portfolio of leading drugs.
The Group’s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology, hematology), which are its primary areas of development. The Group also markets products in other therapeutic areas in which it boasts longstanding expertise (gastroenterology, cardiovascular and cognitive disorders). To a large extent, these are composed of primary care.
Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian…
Petro Bagriy, president of the Association of Drug Manufacturers of Ukraine (AMMU), which gathers seven of the leading Ukrainian pharmaceutical companies, provides insights into the internal workings of the association…
Robert Chagalian, country manager of Siemens Healthineers Ukraine, provides a fascinating insight into the 165-year long presence of Siemens on the Ukrainian market, whilst highlighting the strong commitment of the…
Aleksandr Iavorskyi, founder and president of Biocon, Ukraine’s leading third-party logistics (3PL) company in the pharmaceutical and healthcare areas, provides insights into Biocon’s impressive development and unique partnership approach as…
Victoria Bandyk, chief operating officer of the Bioscience Group, provides insights into the unique added value and the international development of this comprehensive group of companies, which aims to support…
Roman Gladkyi, general manager of Ferring Ukraine, describes the current opportunities and areas for improvement he identifies within Ukraine’s pharmaceutical market and the country’s evolving heath system, with a special…
Evgeniy Gaydukov, Country Director of AstraZeneca Ukraine, provides insights into the remarkable growth that the science-led, innovative company has been experiencing in Ukraine despite the unstable economic situation in the…
Anatoliy Novyk, founder and president of SMC Ecopharm, the only Ukrainian pharmaceutical company to be exclusively focused on its own original drug development, provides insights into Ecopharm’s promising expansion strategy,…
Filya Zhebrovska, chairman of the supervisory board of Farmak and the company’s general director between 1995 and 2017, provides insights into the strategy she has followed to establish Farmak as…
Taras Velgosh, Adamed’s country manager in Ukraine, provides insights into the great results accomplished by the Ukrainian affiliate of this leading Polish pharmaceutical company despite the deep crisis that has…
Liana Maksyoutova, country manager of Polpharma Ukraine, provides insights into the impressive transformation of the Ukrainian affiliate that she has fostered since inheriting its reins in 2012 and how she…
Anatoliy Reder, founder and general director of InterChem, provides insights into the heightened international ambitions of this leading, science-based Ukrainian pharmaceutical company, which plans to leverage its unique R&D and…
Natalia Zago, managing director of Takeda Ukraine, one of the leading international companies operating in the country, provides insights into her main priorities to drive the growth of the company…
See our Cookie Privacy Policy Here
